Pharmaceutical Technology3 小时
Calquence by AstraZeneca for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
Pharmaceutical Technology3 小时
Calquence by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.
Cure Today8 小时
FDA Grants Fast Track Designation to NX-5948 for R/R WM
NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...
Too Old to Operate6 小时
New Standard of Care for Pediatric B-cell ALL
Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.
precisionmedicineonline4 小时
Autologous Cell Therapies in 2024: TILs, TCRs, and T-Cell Toxicities
Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...
MedPage Today5 小时
Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL
The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...
Insider Monkey on MSN2 小时
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?
programmed T-cell therapies for the treatment of cancer and autoimmune diseases. The company’s lead product, AUCATZYL, ...